Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | DZD1516 |
Trade Name | |
Synonyms | DZD-1516|DZD 1516 |
Drug Descriptions |
DZD1516 is an ERBB2 (HER2) inhibitor that penetrates the blood brain barrier, and upon binding to ERRB2 (HER2), prevents ERBB2 (HER2)-dependent signaling, potentially leading to tumor cell death (NCI Drug Dictionary). |
DrugClasses | HER2 Inhibitor 43 |
CAS Registry Number | NA |
NCIT ID | C174039 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Ado-trastuzumab emtansine + DZD1516 | Ado-trastuzumab emtansine DZD1516 | 0 | 1 |
Capecitabine + DZD1516 | Capecitabine DZD1516 | 0 | 1 |
Capecitabine + DZD1516 + Trastuzumab | Capecitabine DZD1516 Trastuzumab | 0 | 1 |
DZD1516 | DZD1516 | 0 | 1 |
DZD1516 + Trastuzumab | DZD1516 Trastuzumab | 0 | 1 |